New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:22 EDTTROVTrovagene to study transrenal BRAF mutations in primary and metastatic cancers
Trovagene announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's proprietary transrenal DNA, or TrDNA, detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
05:16 EDTTROVTrovagene expands collaboration with Genomac
Trovagene announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer. Prospective multi-center studies will involve leading clinical and surgical oncology centers in the Czech Republic. The first study focusing on lung cancer will enroll up to 300 patients, while the second study will enroll up to 500 patients with Stage III-IV colorectal cancer. Colorectal and lung cancer are the two most commonly occurring solid cancers in the Czech Republic.
January 20, 2015
08:18 EDTTROVTrovagene says study results support utility of cancer monitoring platform
Subscribe for More Information
January 15, 2015
07:59 EDTTROVAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 12, 2015
08:35 EDTTROVTrovagene announces clinical collaboratoin with UC San Diego
Trovagene announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the utility of detecting and monitoring EGFR mutations, using its Precision Cancer MonitoringSM platform. This large-scale study expands on the company's clinical programs in lung cancer at Memorial Sloan Kettering Cancer Center and City of Hope Medical Center.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use